Corvus Pharmaceuticals
Corvus Pharmaceuticals's Overview
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies. Their pipeline includes small molecules and antibodies designed to harness the immune system to attack cancer cells. Key programs target various cancer indications, aiming to provide new treatment options for patients with unmet medical needs. They are actively advancing candidates like mupadolimab (anti-CD73), ciforadenant (A2A receptor antagonist), and sovateltide.
Where is Corvus Pharmaceuticals's Headquarters?
HQ Function
The headquarters serves as the central hub for research and development, clinical trial management, corporate strategy, and administrative operations.
Notable Features:
The facility likely includes modern laboratory spaces for drug discovery and development, alongside office areas designed for collaborative work.
Work Culture:
As a clinical-stage biotech, the culture is likely fast-paced, innovative, and science-driven, with a strong emphasis on collaboration and achieving milestones in drug development.
HQ Significance:
Its location in the San Francisco Bay Area provides access to a rich ecosystem of talent, research institutions, venture capital, and potential partners crucial for biotech growth.
Values Reflected in HQ: The headquarters' focus on R&D and clinical operations reflects the company's commitment to scientific innovation and patient-centric drug development.
Location:
Corvus Pharmaceuticals operates primarily from its headquarters in the United States. Its global presence is mainly characterized by the international scope of its clinical trials, collaborations with research institutions worldwide, and partnerships with contract manufacturing and research organizations in various countries to support its drug development pipeline.
Street Address:
863 Mitten Road, Suite 102
City:
Burlingame
State/Province:
CA
Country:
USA
Corvus Pharmaceuticals's Global Presence
Burlingame, CA/Global (Remote/Partner-based)
Address: N/A (Operations primarily centralized at HQ)
To support global clinical development programs and collaborations across various geographies where trials are conducted or research partners are located.
Buying Intent Signals for Corvus Pharmaceuticals
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Corvus Pharmaceuticals
As of April 2025, Corvus Pharmaceuticals' leadership includes:
Investors of Corvus Pharmaceuticals
Corvus Pharmaceuticals has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Based on publicly available information, Corvus Pharmaceuticals' core executive leadership team has remained stable over the last 12 months, with no major new hires or departures announced at the C-suite level.
Technology (Tech Stack) used by Corvus Pharmaceuticals
Discover the tools Corvus Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Corvus Pharmaceuticals Email Formats and Examples
Corvus Pharmaceuticals likely utilizes common corporate email formats. The most probable format combines the first initial and last name of the employee, followed by the @corvuspharma.com domain.
[first_initial][last]@corvuspharma.com
Format
rmiller@corvuspharma.com
Example
80%
Success rate
News and media
GlobeNewswire • May 9, 2024
Corvus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Corvus Pharmaceuticals announced its financial results for the first quarter ending March 31, 2024, and provided updates on its clinical programs, including progress with mupadolimab (anti-CD73) and sovateltide....more
GlobeNewswire • April 8, 2024
Corvus Pharmaceuticals Presents Preclinical Data on Mupadolimab (Anti-CD73) Enhancing Antitumor Immunity at AACR Annual Meeting 2024
Corvus presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2024, highlighting mupadolimab's potential to enhance antitumor immunity by modulating myeloid cells and T cells....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Corvus Pharmaceuticals, are just a search away.